Phaseline

Companies › Belief BioMed (Beijing)

Belief BioMed (Beijing): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Neurology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBM-D101
AAV-mediated gene addition therapy delivering dystrophin-associated protein complex therap
DMDPhase 1DMDJun 2027
BBM-A101–Phase 1Knee OsteoarthritisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07058662BBM-D101Phase 1DMDNeurologyJun 2027
NCT07198555BBM-A101Phase 1Knee OsteoarthritisImmunologyDec 2027

Targets

DMD (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Insmed Gene Therapy Nippon Shinyaku

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.